Vireo Growth (K95) Q2 2026 Earnings Report

The call presents a predominantly positive operational and financial trajectory: exceptionally large reported and pro forma revenue growth, a >$1B annualized run rate, improved adjusted EBITDA and near break‑even net loss, meaningful liquidity, and ambitious footprint expansion. Offsetting these positives are margin compression at the consolidated level driven by lower‑margin non‑cannabis additions and recently acquired businesses, plus execution and regulatory risk as multiple announced transactions await closing and integration.

The company guided that its pro forma Q2 performance puts it on a greater-than-$1.0 billion annualized run rate (pro forma Q2 revenue $254.9M vs. GAAP Q2 revenue $209.3M, +335% YoY), and said it expects to operate roughly 270 dispensaries across 15 states (today ~170 dispensaries in 10 states) upon closing announced deals; management reiterated objectives to generate non‑volatile free cash flow, build $100M+ revenue businesses in each core state, and deliver consistent same‑store sales growth (pro forma cannabis same‑store/retail growth ~7% in the quarter, with a longer‑term target of low single‑digit growth above inflation). Key near‑term financials discussed as context include Q2 cannabis revenue $175.8M (+265% YoY) and non‑cannabis $33.5M, adjusted gross margin 47% excluding non‑cash inventory adjustments (cannabis adj. gross margin 53%, non‑cannabis 18%), adjusted EBITDA ~$41.5M (19.8% of sales; adjusted EBITDA margin down 790 bps YoY to reflect lower‑margin acquisitions and non‑cannabis at 6.3%), Q2 net loss $0.1M (vs. $14.9M loss YoY), cash $122.7M (+$1M marketable securities), and a $65M ABL (expandable to $85M / $105M via accordion) priced at Term SOFR+1.75–2% (currently ~5.37–5.62%); management expects 2027 to provide a clearer financial picture of the strategy.